134 related articles for article (PubMed ID: 29985863)
1. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
2. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
4. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Lo MC; Garioch J; Moncrieff MD
J Plast Reconstr Aesthet Surg; 2020 Jul; 73(7):1263-1267. PubMed ID: 32245735
[TBL] [Abstract][Full Text] [Related]
5. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
6. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.
Read T; Webber S; Tan J; Wagels M; Schaider H; Soyer HP; Smithers BM
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2030-2037. PubMed ID: 28626861
[TBL] [Abstract][Full Text] [Related]
7. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
9. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
[TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Trefzer U; Sterry W
Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
[No Abstract] [Full Text] [Related]
11. Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts.
Suh DW; Lew BL; Sim WY
Int J Dermatol; 2014 Dec; 53(12):e567-71. PubMed ID: 25427069
[TBL] [Abstract][Full Text] [Related]
12. Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
Lôbo MM; Calsavara VF; Ricci BV; Lopes Pinto CA; Bertolli E; Duprat Neto JP
J Am Acad Dermatol; 2020 Dec; 83(6):1812-1813. PubMed ID: 32289400
[No Abstract] [Full Text] [Related]
13. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
14. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS
J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907
[TBL] [Abstract][Full Text] [Related]
15. Case report: Regression of in-transit metastases of cutaneous squamous cell carcinoma with combination pembrolizumab and topical diphencyprone.
Poplausky D; Young JN; Block BR; Estrada Y; Singer GK; Wong V; Cabral P; Suemitsu Y; Kim RH; Friedlander P; Gulati N
Front Oncol; 2024; 14():1294331. PubMed ID: 38800408
[TBL] [Abstract][Full Text] [Related]
16. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
Galadari I; Rubaie S; Alkaabi J; Galadari H
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526
[TBL] [Abstract][Full Text] [Related]
17. Treatment of disseminated facial warts through contact immunotherapy with diphenylcyclopropenone (DPCP).
Aghaei S
Dermatol Online J; 2006 Feb; 12(2):10. PubMed ID: 16638403
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients.
Chiang KS; Mesinkovska NA; Piliang MP; Bergfeld WF
J Investig Dermatol Symp Proc; 2015 Nov; 17(2):50-5. PubMed ID: 26551948
[TBL] [Abstract][Full Text] [Related]
19. Topical immunomodulation with diphenylcyclopropenone for alopecia areata: the Lebanese experience.
El Khoury J; Abd-el-Baki J; Succariah F; Abbas O; Kibbi AG; Kurban M
Int J Dermatol; 2013 Dec; 52(12):1551-6. PubMed ID: 24134785
[TBL] [Abstract][Full Text] [Related]
20. Topical immunotherapy with diphenylcyclopropenone in vitiligo: a preliminary experience.
Aghaei S; Ardekani GS
Indian J Dermatol Venereol Leprol; 2008; 74(6):628-31. PubMed ID: 19171989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
